Poseida Therapeutics, Inc.
PSTX · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $65 | $130 | $0 | $0 |
| % Growth | -50.4% | 417,217.1% | – | – |
| Cost of Goods Sold | $157 | $5 | $5 | $3 |
| Gross Profit | -$92 | $125 | -$5 | -$3 |
| % Margin | -142.3% | 96% | -14,472% | – |
| R&D Expenses | $157 | $153 | $0 | $0 |
| G&A Expenses | $37 | $38 | $0 | $0 |
| SG&A Expenses | $37 | $38 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $3 | $0 | $0 |
| Operating Expenses | $194 | $190 | $0 | $0 |
| Operating Income | -$130 | -$60 | -$0 | -$0 |
| % Margin | -200.2% | -46% | -452.7% | – |
| Other Income/Exp. Net | $6 | -$4 | $16 | -$130 |
| Pre-Tax Income | -$123 | -$63 | -$0 | -$0 |
| Tax Expense | $0 | $1 | -$5 | -$3 |
| Net Income | -$123 | -$64 | $4 | $2 |
| % Margin | -190.8% | -49.1% | 14,097.8% | – |
| EPS | -1.37 | -0.89 | 0.071 | 0.042 |
| % Growth | -53.9% | -1,357.1% | 68.6% | – |
| EPS Diluted | -1.37 | -0.89 | 0.071 | 0.042 |
| Weighted Avg Shares Out | 90 | 72 | 62 | 58 |
| Weighted Avg Shares Out Dil | 90 | 72 | 62 | 58 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $4 |
| Interest Expense | $9 | $6 | $3 | $0 |
| Depreciation & Amortization | $6 | $5 | $5 | $3 |
| EBITDA | -$109 | -$52 | -$117 | -$145 |
| % Margin | -168.5% | -39.8% | -374,748.7% | – |